Highmark and Spravato™ (Esketamine) – Is It Covered?

Does Highmark cover Spravato™ (Esketamine)?

Highmark may cover Spravato (Esketamine), but whether your treatment is approved depends on your specific plan, your medical history, and how your diagnosis fits Highmark’s clinical criteria. At Libertas Mind, we work closely with Highmark and help patients secure prior authorizations so they can access Spravato treatment with minimal delays.

Highmark requires a thorough review before approving Spravato. This includes confirming your diagnosis, reviewing your past treatment history, and making sure Spravato will be administered in an appropriate, certified medical setting. Our team guides you through each step of this process clearly and supportively.

Highmark Spravato™ (Esketamine) Coverage Requirements

  • 18 years of age or older
  • Treatment-resistant depression (TRD)
  • Major depressive disorder (MDD) with acute suicidal ideation or behavior
  • Depression is diagnosed with an approved tool such as the PHQ-9
  • Spravato is used alongside an oral antidepressant
  • Treatment administered under supervision in a certified healthcare setting
  • Blood pressure was assessed before and after each treatment
  • Provider monitors for sedation or dissociation for at least two hours after dosing
  • Healthcare setting, pharmacy, and patient registered with the required safety program (REMS)
  • Provider monitors for clinical worsening or the emergence of suicidal thoughts
  • No disqualifying medical conditions or recent severe substance use disorders
     

These requirements ensure Spravato is given safely and appropriately, and they help Highmark determine medical necessity.

How to Check BCBS Spravato™ (Esketamine) Coverage

Libertas Mind is in-network with many Highmark plans. Our care coordinators can help you:

We handle the complex steps so you can focus on feeling better.

Why Spravato™ (Esketamine) Matters for Treating Depression

Spravato is an innovative treatment for:

• Treatment-resistant depression
• Major depressive disorder with suicidal ideation

Studies show Spravato can bring rapid improvement when traditional medications have not worked — with an effectiveness rate of 40–60% depending on treatment duration.

Spravato is derived from ketamine and administered as a nasal spray only inside a certified medical setting. It cannot be taken home or picked up at a normal pharmacy because of required monitoring and safety protocols.

Libertas Mind Accepts Blue Cross Blue Shield Insurance

Our experienced care team is ready to help you understand whether your Spravato treatment can be covered by BCBS and walk you through every step: verification, authorization, scheduling, and follow-ups.

Contact us today to get started on your treatment journey.

FAQs About Highmark and Spravato™ (Esketamine) Coverage

Highmark may cover Spravato, but approval depends on your specific plan, diagnosis, and meeting strict medical-necessity criteria. Prior authorization is usually required.

You must be 18 or older, have treatment-resistant depression or MDD with suicidal ideation, and meet all safety requirements such as PHQ-9 diagnosis, supervised administration, and REMS enrollment.

Due to potential side effects like sedation and dissociation, Spravato must be administered in a monitored medical environment with two-hour observation to ensure patient safety.

Yes. Highmark requires detailed documentation, including diagnosis, treatment history, and monitoring plans, before approving Spravato treatment.

 

Your costs depend on your plan’s benefits. Some members may have copays, deductibles, or coinsurance. Libertas Mind can help estimate these costs.

Absolutely. Our team can verify your benefits, manage your prior authorization, and guide you through scheduling treatment at a certified facility.